Literature DB >> 7868970

Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.

M Chen1, J L Breslow, W Li, T Leff.   

Abstract

Insulin-dependent diabetes mellitus (IDDM) is associated with elevated plasma triglyceride levels that normalize after insulin administration. The observation that overexpression of the apoC-III gene in transgenic mice can cause hypertriglyceridemia and other evidence implicating apoC-III in the regulation of triglyceride levels prompted us to examine whether apoC-III might be involved in the hypertriglyceridemia associated with IDDM. To this end, the regulation of apoC-III gene expression was studied in the streptozotocin-treated mouse model of IDDM. In the insulin-deficient diabetic state, these mice have elevated glucose and triglyceride levels and a 1.4- to 1.5-fold increase in hepatic apoC-III mRNA levels, by Northern analysis as well as quantitative solution hybridization RNase protection assay. Insulin treatment normalized the glucose and triglyceride levels and diminished hepatic apoC-III mRNA levels by 59%. Analysis of transcription rates using the nuclear run-on technique demonstrated that the changes in hepatic apoC-III mRNA levels were the results of changes in the transcriptional activity of the gene. To determine the role of insulin in the regulation of apoC-III transcription, HepG2 cells were transfected with an apoC-III reporter construct, and treated with different insulin concentrations. The results demonstrated that insulin treatment induced a dose-dependent down-regulation of apoC-III transcriptional activity. These data suggest that the apoC-III transcriptional changes seen in animals are caused by differences in insulin concentrations. Assuming that apoC-III mRNA levels reflect the synthesis and secretion of the protein, these results present the possibility that overexpression of the apoC-III gene could contribute to the hypertriglyceridemia observed in IDDM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7868970

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  54 in total

Review 1.  New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c.

Authors:  Fabienne Foufelle; Pascal Ferré
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

2.  Impaired postprandial lipemic response in chronic kidney disease.

Authors:  Jeffrey M Saland; Lisa M Satlin; Jeanna Zalsos-Johnson; Serge Cremers; Henry N Ginsberg
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

3.  Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy.

Authors:  Andrea Kassai; Ranganath Muniyappa; Amy E Levenson; Mary F Walter; Brent S Abel; Michael Ring; Simeon I Taylor; Sudha B Biddinger; Monica C Skarulis; Phillip Gorden; Rebecca J Brown
Journal:  J Clin Endocrinol Metab       Date:  2016-02-22       Impact factor: 5.958

4.  Why there is an IRS.

Authors:  R M O'Brien; D K Granner
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Key differences between apoC-III regulation and expression in intestine and liver.

Authors:  Gabrielle West; Cayla Rodia; Diana Li; Zania Johnson; Hongli Dong; Alison B Kohan
Journal:  Biochem Biophys Res Commun       Date:  2017-07-21       Impact factor: 3.575

6.  Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

Authors:  Arman Qamar; Sumeet A Khetarpal; Amit V Khera; Atif Qasim; Daniel J Rader; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-11       Impact factor: 8.311

Review 7.  Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.

Authors:  Piers R Blackett; Dharambir K Sanghera
Journal:  J Clin Lipidol       Date:  2012-04-22       Impact factor: 4.766

Review 8.  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

Authors:  Iciar Martín-Timón; Cristina Sevillano-Collantes; Amparo Segura-Galindo; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2014-08-15

9.  Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?

Authors:  Henry N Ginsberg; Gissette Reyes-Soffer
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

10.  Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.

Authors:  Jenny E Kanter; Baohai Shao; Farah Kramer; Shelley Barnhart; Masami Shimizu-Albergine; Tomas Vaisar; Mark J Graham; Rosanne M Crooke; Clarence R Manuel; Rebecca A Haeusler; Daniel Mar; Karol Bomsztyk; John E Hokanson; Gregory L Kinney; Janet K Snell-Bergeon; Jay W Heinecke; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2019-07-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.